MedTrace Logo

IMRT Followed by CyberKnife Boost Focused on the Gross Residual Pelvic Tumor Volume

NCT03206385 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-06-22

No results posted yet for this study

Summary

The present register has been designed to confirm the hypothesis that while using high quality Intensity Modulated Radiation Techniques (IMRT) and a reduced external beam stereotactic boost component it would be possible to maintain the late severe toxicity rates under the 5 % level in situations where brachytherapy could not be proposed as a boost.

Conditions

  • Pelvis Tumors

Interventions

RADIATION

Radiation treatment

50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.

RADIATION

CK Boost Pelvis

Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR

Sponsors & Collaborators

  • Centre Francois Baclesse, Luxembourg

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Luxembourg

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03206385 on ClinicalTrials.gov